Ignite Creation Date:
2025-12-24 @ 12:01 PM
Ignite Modification Date:
2026-02-25 @ 6:57 PM
Study NCT ID:
NCT02059161
Status:
COMPLETED
Last Update Posted:
2018-09-05
First Post:
2014-02-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Australia', 'Colombia', 'Mexico', 'New Zealand', 'Peru', 'South Africa', 'Spain', 'United States']}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000629534', 'term': 'MK-1293'}, {'id': 'D000069036', 'term': 'Insulin Glargine'}], 'ancestors': [{'id': 'D049528', 'term': 'Insulin, Long-Acting'}, {'id': 'D061385', 'term': 'Insulins'}, {'id': 'D010187', 'term': 'Pancreatic Hormones'}, {'id': 'D036361', 'term': 'Peptide Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrialsDisclosure@merck.com', 'phone': '1-800-672-6372', 'title': 'Senior Vice President, Global Clinical Development', 'organization': 'Merck Sharp & Dohme Corp.'}, 'certainAgreement': {'otherDetails': 'The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Up to 54 weeks', 'description': 'The safety population consisted of all randomized participants who received at least one dose of study treatment.', 'eventGroups': [{'id': 'EG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).', 'otherNumAtRisk': 241, 'otherNumAffected': 190, 'seriousNumAtRisk': 241, 'seriousNumAffected': 23}, {'id': 'EG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).', 'otherNumAtRisk': 258, 'otherNumAffected': 216, 'seriousNumAtRisk': 258, 'seriousNumAffected': 30}], 'otherEvents': [{'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 23, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 29, 'numAffected': 23}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 40, 'numAffected': 27}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 34, 'numAffected': 28}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 7617, 'numAffected': 185}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 7544, 'numAffected': 204}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}], 'seriousEvents': [{'term': 'Angina unstable', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Cardiac failure congestive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Gastric haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'bile duct stone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Cholecystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Cholecystitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Postoperative wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Oseomyelitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Pelvic fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Upper limb fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Diabetic ketoacidosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 8, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 14, 'numAffected': 11}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Breast cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Ovarian adenoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Hypoglycaemic seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 4, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Hypoglycaemic unconsciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'VIth nerve paresis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 3, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Diabetic foot', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Aortic aneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Peripheral vascular disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Ankle fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Coronary artery stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Localised infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Foot fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Rectal cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 241, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 258, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.62', 'groupId': 'OG000', 'lowerLimit': '-0.79', 'upperLimit': '-0.45'}, {'value': '-0.66', 'groupId': 'OG001', 'lowerLimit': '-0.82', 'upperLimit': '-0.50'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.04', 'ciLowerLimit': '-0.11', 'ciUpperLimit': '0.19', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE', 'nonInferiorityComment': 'The criterion for declaring non-inferiority was for the upper bound of the 95% CI to lie below 0.4%.'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 24', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 24 A1C minus the Week 0 A1C.', 'unitOfMeasure': 'Percent', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Any Confirmed Positive Anti-insulin Antibody (AIA) at Any Time Up Through Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '70.1', 'groupId': 'OG000'}, {'value': '74.0', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Percentages', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.9', 'ciLowerLimit': '-11.8', 'ciUpperLimit': '4.0', 'estimateComment': 'Miettinen \\& Nurminen', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Week 24', 'description': 'Percentage of participants with confirmed positive AIA at any time up through Week 24 including baseline.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had data for AIA at or before Week 24.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '101', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '32.7', 'groupId': 'OG000'}, {'value': '35.7', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in Percentages', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.0', 'ciLowerLimit': '-16.1', 'ciUpperLimit': '10.1', 'estimateComment': 'Miettinen \\& Nurminen', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Week 24', 'description': 'Percentage of participants who became positive to AIA at or before Week 24, among participants who were AIA negative at baseline.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who were AIA negative at baseline and had data for AIA at or before Week 24.'}, {'type': 'PRIMARY', 'title': 'Change From Baseline in AIA Titer After 24 Weeks of Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '185', 'groupId': 'OG000'}, {'value': '198', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.4', 'spread': '15.9', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '23.2', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 24', 'description': 'This immunogenicity analysis will assess the effect of treatment with MK-1293 compared with Lantus on anti-insulin antibody development after 24 weeks of treatment. This change from baseline reflects the Week 24 AIA titer minus the Week 0 AIA titer.', 'unitOfMeasure': 'AIA Titers', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had AIA data at baseline and Week 24.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '232', 'groupId': 'OG000'}, {'value': '246', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000'}, {'value': '5.3', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Week 24', 'description': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24. This immunogenicity analysis assessed the effect of treatment with MK-1293 and with Lantus on insulin-neutralizing antibody (INab) development up through 24 weeks of treatment.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who were INAb negative at baseline and who had data for INAb at or before Week 24.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in A1C at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.35', 'groupId': 'OG000', 'lowerLimit': '-0.53', 'upperLimit': '-0.17'}, {'value': '-0.33', 'groupId': 'OG001', 'lowerLimit': '-0.50', 'upperLimit': '-0.16'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.02', 'ciLowerLimit': '-0.18', 'ciUpperLimit': '0.14', 'estimateComment': 'Longitudinal data analysis including terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 52', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 52 A1C minus the Week 0 A1C.', 'unitOfMeasure': 'Percent', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Total Insulin Dose at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '224', 'groupId': 'OG000'}, {'value': '235', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '58.74', 'groupId': 'OG000', 'lowerLimit': '53.39', 'upperLimit': '64.10'}, {'value': '60.51', 'groupId': 'OG001', 'lowerLimit': '55.21', 'upperLimit': '65.81'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.77', 'ciLowerLimit': '-4.69', 'ciUpperLimit': '1.16', 'estimateComment': 'Longitudinal data analysis including terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).', 'unitOfMeasure': 'Insulin units', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '224', 'groupId': 'OG000'}, {'value': '235', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.75', 'groupId': 'OG000', 'lowerLimit': '0.69', 'upperLimit': '0.81'}, {'value': '0.77', 'groupId': 'OG001', 'lowerLimit': '0.72', 'upperLimit': '0.83'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.02', 'ciLowerLimit': '-0.06', 'ciUpperLimit': '0.01', 'estimateComment': 'Longitudinal data analysis including terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).', 'unitOfMeasure': 'Insulin units/kg.', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '-16.8', 'groupId': 'OG000', 'lowerLimit': '-33.4', 'upperLimit': '-0.2'}, {'value': '-26.4', 'groupId': 'OG001', 'lowerLimit': '-42.5', 'upperLimit': '-10.3'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.6', 'ciLowerLimit': '-3.0', 'ciUpperLimit': '22.2', 'estimateComment': 'Longitudinal data analysis including terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 24', 'description': 'Blood glucose was measured on a fasting basis (collected after a 10-hour fast). FPG is expressed as mg/dL. This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.', 'unitOfMeasure': 'mg/dL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Confirmed Positive AIA Up Through Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '73.4', 'groupId': 'OG000'}, {'value': '75.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Differences in Percentages', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.1', 'ciLowerLimit': '-9.8', 'ciUpperLimit': '5.5', 'estimateComment': 'Miettinen \\& Nurminen', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Week 52 including baseline', 'description': 'Percentage of participants with confirmed positive AIA at any time up through Week 52 including baseline.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had data for AIA at or before Week 52.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '101', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '40.6', 'groupId': 'OG000'}, {'value': '39.8', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in Percentages', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.8', 'ciLowerLimit': '-12.8', 'ciUpperLimit': '14.3', 'estimateComment': 'Miettinen \\& Nurminen', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Week 52', 'description': 'Percentage of participants who became positive to AIA at or before Week 52, among participants who were AIA negative at baseline.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had data for AIA at baseline and Week 52.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in AIA Titer After 52 Weeks of Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '164', 'groupId': 'OG000'}, {'value': '177', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.6', 'spread': '9.9', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '20.3', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 52', 'description': 'This immunogenicity analysis assessed the effect of treatment with MK-1293 compared with Lantus on anti-insulin antibody development after 52 weeks of treatment. This change from baseline reflects the AIA titers at Week 52 minus the AIA titers at Week 0.', 'unitOfMeasure': 'AIA Titers', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had AIA data at baseline and Week 52.'}, {'type': 'SECONDARY', 'title': 'Total Insulin Dose at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '228', 'groupId': 'OG000'}, {'value': '240', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '59.16', 'groupId': 'OG000', 'lowerLimit': '53.97', 'upperLimit': '64.34'}, {'value': '60.93', 'groupId': 'OG001', 'lowerLimit': '55.79', 'upperLimit': '66.06'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the least squares means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.77', 'ciLowerLimit': '-4.92', 'ciUpperLimit': '1.39', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 52', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).', 'unitOfMeasure': 'Insulin units', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '228', 'groupId': 'OG000'}, {'value': '240', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.75', 'groupId': 'OG000', 'lowerLimit': '0.70', 'upperLimit': '0.81'}, {'value': '0.77', 'groupId': 'OG001', 'lowerLimit': '0.71', 'upperLimit': '0.82'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the least squares means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.02', 'ciLowerLimit': '-0.05', 'ciUpperLimit': '0.02', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 52', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).', 'unitOfMeasure': 'Insulin units/kg.', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in FPG at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '-17.9', 'groupId': 'OG000', 'lowerLimit': '-35.8', 'upperLimit': '0.1'}, {'value': '-12.5', 'groupId': 'OG001', 'lowerLimit': '-29.9', 'upperLimit': '4.9'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-5.4', 'ciLowerLimit': '-19.7', 'ciUpperLimit': '8.9', 'estimateComment': 'Longitudinal data analysis including terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 52', 'description': 'Blood glucose was measured on a fasting basis (collected after a 10-hour fast). This change from baseline reflects the FPG level at Week 52 minus the FPG level at Week 0.', 'unitOfMeasure': 'mg/dL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '232', 'groupId': 'OG000'}, {'value': '246', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '4.7', 'groupId': 'OG000'}, {'value': '6.9', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to Week 52', 'description': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Thought Week 52. This immunogenicity analysis assessed the effect of treatment with MK-1293 and with Lantus on insulin-neutralizing antibody (INAb) development up through 52 weeks of treatment.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who were INAb negative at baseline and who had data for INAb at or before Week 52.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '226', 'groupId': 'OG000'}, {'value': '248', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.9', 'groupId': 'OG000', 'lowerLimit': '-15.8', 'upperLimit': '5.9'}, {'value': '-4.6', 'groupId': 'OG001', 'lowerLimit': '-14.9', 'upperLimit': '5.8'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.4', 'ciLowerLimit': '-8.9', 'ciUpperLimit': '8.2', 'estimateComment': 'Longitudinal data analysis model including terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 24', 'description': 'The 7-point SMBG profile consisted of the following measurements by glucose meter: morning pre-meal (fasting), 2 hours after morning meal, midday pre-meal, 2 hours after midday meal, evening pre meal, pre-bedtime (pre-dose and at least 2 hours after evening meal), between 2:00 AM and 4:00 AM in the morning.', 'unitOfMeasure': 'mg/dL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 7-point SMBG at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '229', 'groupId': 'OG000'}, {'value': '249', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '-12.0', 'groupId': 'OG000', 'lowerLimit': '-25.8', 'upperLimit': '1.7'}, {'value': '-4.0', 'groupId': 'OG001', 'lowerLimit': '-16.3', 'upperLimit': '8.4'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-8.1', 'ciLowerLimit': '-18.6', 'ciUpperLimit': '2.4', 'estimateComment': 'Longitudinal data analysis including terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 52', 'description': 'The 7-point SMBG profile consisted of the following measurements by glucose meter: morning pre-meal (fasting), 2 hours after morning meal, midday pre-meal, 2 hours after midday meal, evening pre meal, pre-bedtime (pre-dose and at least 2 hours after evening meal), between 2:00 AM and 4:00 AM in the morning.', 'unitOfMeasure': 'mg/dL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 24 Weeks of Treatment.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '219', 'groupId': 'OG000'}, {'value': '236', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'title': 'A1C < 7.0%', 'categories': [{'measurements': [{'value': '37.0', 'groupId': 'OG000'}, {'value': '37.7', 'groupId': 'OG001'}]}]}, {'title': 'A1C < 6.5%', 'categories': [{'measurements': [{'value': '20.5', 'groupId': 'OG000'}, {'value': '21.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted Difference in %s (A1C < 7.0%)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.8', 'ciLowerLimit': '-9.7', 'ciUpperLimit': '8.1', 'estimateComment': 'Miettinen and Nurminen, stratified by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted Difference in %s (A1C <6.5%)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.1', 'ciLowerLimit': '-8.6', 'ciUpperLimit': '6.5', 'estimateComment': 'Miettinen and Nurminen, stratified by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'NUMBER', 'timeFrame': '24 weeks', 'description': 'Percentage of participants attaining A1C glycemic goals of \\<7.0% and \\<6.5% after 24 weeks of treatment.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants with a Week 24 A1C measurement.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 52 Weeks of Treatment.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '197', 'groupId': 'OG000'}, {'value': '221', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'title': 'A1C < 7.0%', 'categories': [{'measurements': [{'value': '31.0', 'groupId': 'OG000'}, {'value': '30.8', 'groupId': 'OG001'}]}]}, {'title': 'A1C < 6.5%', 'categories': [{'measurements': [{'value': '14.2', 'groupId': 'OG000'}, {'value': '18.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted Difference (A1C < 7.0%)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.2', 'ciLowerLimit': '-8.7', 'ciUpperLimit': '9.1', 'estimateComment': 'Miettinen and Nurminen', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted Difference (A1C < 6.5%)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.4', 'ciLowerLimit': '-11.5', 'ciUpperLimit': '2.8', 'estimateComment': 'Miettinen and Nurminen', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'NUMBER', 'timeFrame': '52 weeks', 'description': 'Percentage of participants attaining A1C glycemic goals of \\<7.0% and \\<6.5% after 52 weeks of treatment.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants with a Week 52 A1C measurement.'}, {'type': 'SECONDARY', 'title': 'Basal Insulin Dose at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '36.08', 'groupId': 'OG000', 'lowerLimit': '33.14', 'upperLimit': '39.03'}, {'value': '36.51', 'groupId': 'OG001', 'lowerLimit': '33.63', 'upperLimit': '39.39'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in Least Means Squares', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.42', 'ciLowerLimit': '-2.33', 'ciUpperLimit': '1.48', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 52', 'description': 'Basal Insulin Dose at Week 52.', 'unitOfMeasure': 'Units', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Basal Insulin Dose Per kg of Body Weight at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.46', 'groupId': 'OG000', 'lowerLimit': '0.43', 'upperLimit': '0.50'}, {'value': '0.47', 'groupId': 'OG001', 'lowerLimit': '0.43', 'upperLimit': '0.50'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in Least Means Squares', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.00', 'ciLowerLimit': '-0.02', 'ciUpperLimit': '0.02', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 52', 'description': 'Basal Insulin Dose per kg of Body Weight at Week 52.', 'unitOfMeasure': 'Units/kg', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Bolus Insulin Dose at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '228', 'groupId': 'OG000'}, {'value': '240', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '22.15', 'groupId': 'OG000', 'lowerLimit': '19.03', 'upperLimit': '25.27'}, {'value': '23.65', 'groupId': 'OG001', 'lowerLimit': '20.57', 'upperLimit': '26.73'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.50', 'ciLowerLimit': '-3.69', 'ciUpperLimit': '0.69', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 52', 'description': 'Bolus Insulin Dose at Week 52.', 'unitOfMeasure': 'Units', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Bolus Insulin Dose Per kg of Body Weight at Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '228', 'groupId': 'OG000'}, {'value': '240', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.28', 'groupId': 'OG000', 'lowerLimit': '0.24', 'upperLimit': '0.31'}, {'value': '0.30', 'groupId': 'OG001', 'lowerLimit': '0.26', 'upperLimit': '0.33'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciPctValue': '95', 'paramValue': '-0.02', 'ciLowerLimit': '-0.04', 'ciUpperLimit': '0.01', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 52', 'description': 'Bolus Insulin Dose per kg of Body Weight at Week 52.', 'unitOfMeasure': 'Units/kg', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Basal Insulin Dose at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '36.33', 'groupId': 'OG000', 'lowerLimit': '33.24', 'upperLimit': '39.42'}, {'value': '37.07', 'groupId': 'OG001', 'lowerLimit': '34.03', 'upperLimit': '40.12'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.74', 'ciLowerLimit': '-2.52', 'ciUpperLimit': '1.04', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'Basal Insulin Dose at Week 24.', 'unitOfMeasure': 'Units', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Basal Insulin Dose Per kg of Body Weight at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '258', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.46', 'groupId': 'OG000', 'lowerLimit': '0.43', 'upperLimit': '0.50'}, {'value': '0.48', 'groupId': 'OG001', 'lowerLimit': '0.44', 'upperLimit': '0.51'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.01', 'ciLowerLimit': '-0.03', 'ciUpperLimit': '0.01', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'Basal Insulin Dose per kg of Body Weight at Week 24.', 'unitOfMeasure': 'Units/kg', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Bolus Insulin Dose at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '224', 'groupId': 'OG000'}, {'value': '235', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '21.65', 'groupId': 'OG000', 'lowerLimit': '18.50', 'upperLimit': '24.81'}, {'value': '22.91', 'groupId': 'OG001', 'lowerLimit': '19.80', 'upperLimit': '26.02'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.25', 'ciLowerLimit': '-3.34', 'ciUpperLimit': '0.83', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'Bolus Insulin Dose at Week 24.', 'unitOfMeasure': 'Units', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}, {'type': 'SECONDARY', 'title': 'Bolus Insulin Dose Per kg of Body Weight at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '224', 'groupId': 'OG000'}, {'value': '235', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'OG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.28', 'groupId': 'OG000', 'lowerLimit': '0.24', 'upperLimit': '0.31'}, {'value': '0.29', 'groupId': 'OG001', 'lowerLimit': '0.26', 'upperLimit': '0.33'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in the Least Squares Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.02', 'ciLowerLimit': '-0.04', 'ciUpperLimit': '0.01', 'estimateComment': 'Longitudinal data analysis model included terms for treatment, time, prior insulin status (intermediate-acting, or long-acting insulin), and the interaction of time by treatment, and time by prior insulin status.', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'Bolus Insulin Dose per kg of Body Weight at Week 24.', 'unitOfMeasure': 'Units/kg', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'FG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '245'}, {'groupId': 'FG001', 'numSubjects': '263'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '241'}, {'groupId': 'FG001', 'numSubjects': '258'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '196'}, {'groupId': 'FG001', 'numSubjects': '222'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '49'}, {'groupId': 'FG001', 'numSubjects': '41'}]}], 'dropWithdraws': [{'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '12'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '13'}]}, {'type': 'Randomized in error, no study drug', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Non-compliance with study drug', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '2'}]}]}], 'recruitmentDetails': 'Participants at least 18 years of age who have had Type 1 diabetes mellitus (T1DM) for at least one year prior to study start.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '245', 'groupId': 'BG000'}, {'value': '263', 'groupId': 'BG001'}, {'value': '508', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'BG001', 'title': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '41.8', 'spread': '14.5', 'groupId': 'BG000'}, {'value': '41.6', 'spread': '14.8', 'groupId': 'BG001'}, {'value': '41.7', 'spread': '14.6', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '106', 'groupId': 'BG000'}, {'value': '111', 'groupId': 'BG001'}, {'value': '217', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '139', 'groupId': 'BG000'}, {'value': '152', 'groupId': 'BG001'}, {'value': '291', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The analysis population included all randomized participants.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 508}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-10-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-08', 'completionDateStruct': {'date': '2015-11-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-08-07', 'studyFirstSubmitDate': '2014-02-07', 'resultsFirstSubmitDate': '2017-01-17', 'studyFirstSubmitQcDate': '2014-02-07', 'lastUpdatePostDateStruct': {'date': '2018-09-05', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-01-17', 'studyFirstPostDateStruct': {'date': '2014-02-11', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2017-03-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2015-05-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24', 'timeFrame': 'Baseline and Week 24', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 24 A1C minus the Week 0 A1C.'}, {'measure': 'Percentage of Participants With Any Confirmed Positive Anti-insulin Antibody (AIA) at Any Time Up Through Week 24', 'timeFrame': 'Up to Week 24', 'description': 'Percentage of participants with confirmed positive AIA at any time up through Week 24 including baseline.'}, {'measure': 'Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 24', 'timeFrame': 'Up to Week 24', 'description': 'Percentage of participants who became positive to AIA at or before Week 24, among participants who were AIA negative at baseline.'}, {'measure': 'Change From Baseline in AIA Titer After 24 Weeks of Treatment', 'timeFrame': 'Baseline and Week 24', 'description': 'This immunogenicity analysis will assess the effect of treatment with MK-1293 compared with Lantus on anti-insulin antibody development after 24 weeks of treatment. This change from baseline reflects the Week 24 AIA titer minus the Week 0 AIA titer.'}, {'measure': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24', 'timeFrame': 'Up to Week 24', 'description': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24. This immunogenicity analysis assessed the effect of treatment with MK-1293 and with Lantus on insulin-neutralizing antibody (INab) development up through 24 weeks of treatment.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in A1C at Week 52', 'timeFrame': 'Baseline and Week 52', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 52 A1C minus the Week 0 A1C.'}, {'measure': 'Total Insulin Dose at Week 24', 'timeFrame': 'Week 24', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).'}, {'measure': 'Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 24', 'timeFrame': 'Week 24', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24', 'timeFrame': 'Baseline and Week 24', 'description': 'Blood glucose was measured on a fasting basis (collected after a 10-hour fast). FPG is expressed as mg/dL. This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.'}, {'measure': 'Percentage of Participants With Confirmed Positive AIA Up Through Week 52', 'timeFrame': 'Up to Week 52 including baseline', 'description': 'Percentage of participants with confirmed positive AIA at any time up through Week 52 including baseline.'}, {'measure': 'Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 52', 'timeFrame': 'Up to Week 52', 'description': 'Percentage of participants who became positive to AIA at or before Week 52, among participants who were AIA negative at baseline.'}, {'measure': 'Change From Baseline in AIA Titer After 52 Weeks of Treatment', 'timeFrame': 'Baseline and Week 52', 'description': 'This immunogenicity analysis assessed the effect of treatment with MK-1293 compared with Lantus on anti-insulin antibody development after 52 weeks of treatment. This change from baseline reflects the AIA titers at Week 52 minus the AIA titers at Week 0.'}, {'measure': 'Total Insulin Dose at Week 52', 'timeFrame': 'Week 52', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).'}, {'measure': 'Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 52', 'timeFrame': 'Week 52', 'description': 'Total insulin dose = basal insulin (MK-1293 or Lantus) + bolus (prandial) insulin (non-study medication).'}, {'measure': 'Change From Baseline in FPG at Week 52', 'timeFrame': 'Baseline and Week 52', 'description': 'Blood glucose was measured on a fasting basis (collected after a 10-hour fast). This change from baseline reflects the FPG level at Week 52 minus the FPG level at Week 0.'}, {'measure': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 52', 'timeFrame': 'Up to Week 52', 'description': 'Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Thought Week 52. This immunogenicity analysis assessed the effect of treatment with MK-1293 and with Lantus on insulin-neutralizing antibody (INAb) development up through 52 weeks of treatment.'}, {'measure': 'Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) at Week 24', 'timeFrame': 'Baseline and Week 24', 'description': 'The 7-point SMBG profile consisted of the following measurements by glucose meter: morning pre-meal (fasting), 2 hours after morning meal, midday pre-meal, 2 hours after midday meal, evening pre meal, pre-bedtime (pre-dose and at least 2 hours after evening meal), between 2:00 AM and 4:00 AM in the morning.'}, {'measure': 'Change From Baseline in 7-point SMBG at Week 52', 'timeFrame': 'Baseline and Week 52', 'description': 'The 7-point SMBG profile consisted of the following measurements by glucose meter: morning pre-meal (fasting), 2 hours after morning meal, midday pre-meal, 2 hours after midday meal, evening pre meal, pre-bedtime (pre-dose and at least 2 hours after evening meal), between 2:00 AM and 4:00 AM in the morning.'}, {'measure': 'Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 24 Weeks of Treatment.', 'timeFrame': '24 weeks', 'description': 'Percentage of participants attaining A1C glycemic goals of \\<7.0% and \\<6.5% after 24 weeks of treatment.'}, {'measure': 'Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 52 Weeks of Treatment.', 'timeFrame': '52 weeks', 'description': 'Percentage of participants attaining A1C glycemic goals of \\<7.0% and \\<6.5% after 52 weeks of treatment.'}, {'measure': 'Basal Insulin Dose at Week 52', 'timeFrame': 'Week 52', 'description': 'Basal Insulin Dose at Week 52.'}, {'measure': 'Basal Insulin Dose Per kg of Body Weight at Week 52', 'timeFrame': 'Week 52', 'description': 'Basal Insulin Dose per kg of Body Weight at Week 52.'}, {'measure': 'Bolus Insulin Dose at Week 52', 'timeFrame': 'Week 52', 'description': 'Bolus Insulin Dose at Week 52.'}, {'measure': 'Bolus Insulin Dose Per kg of Body Weight at Week 52', 'timeFrame': 'Week 52', 'description': 'Bolus Insulin Dose per kg of Body Weight at Week 52.'}, {'measure': 'Basal Insulin Dose at Week 24', 'timeFrame': 'Week 24', 'description': 'Basal Insulin Dose at Week 24.'}, {'measure': 'Basal Insulin Dose Per kg of Body Weight at Week 24', 'timeFrame': 'Week 24', 'description': 'Basal Insulin Dose per kg of Body Weight at Week 24.'}, {'measure': 'Bolus Insulin Dose at Week 24', 'timeFrame': 'Week 24', 'description': 'Bolus Insulin Dose at Week 24.'}, {'measure': 'Bolus Insulin Dose Per kg of Body Weight at Week 24', 'timeFrame': 'Week 24', 'description': 'Bolus Insulin Dose per kg of Body Weight at Week 24.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Type 1 Diabetes Mellitus']}, 'referencesModule': {'references': [{'pmid': '29766635', 'type': 'DERIVED', 'citation': 'Home PD, Lam RLH, Carofano WL, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rosenstock J, Hollander PA, Gallwitz B. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. Diabetes Obes Metab. 2018 Sep;20(9):2220-2228. doi: 10.1111/dom.13354. Epub 2018 Jun 5.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare the safety and efficacy of MK-1293 to Lantus™ in participants with T1DM. The primary hypothesis is that after 24 weeks, the mean change in hemoglobin A1c (A1C) from baseline is non-inferior in participants treated with MK-1293 compared with participants treated with Lantus™.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* T1DM For at least 1 year\n* is currently using or has been using prandial insulin for at least 4 weeks. Participants taking any type of basal insulin should require a total daily dose of \\>=10 units/day. For participants currently taking pre-mixed insulin, the basal insulin component should be equivalent to a total daily dose of \\>=10 units/day.\n* is male, or is female who is not of reproductive potential or if of reproductive potential agrees to remain abstinent or use (or have their partner use) an acceptable method of birth control during the study and for 14 days after the last dose of study medication\n\nExclusion Criteria:\n\n* has had 1 or more severe hypoglycemic episodes associated with hypoglycemic seizure or loss of consciousness within the past 6 months\n* history of ketoacidosis in the last 6 months\n* participant, as assessed by the investigator, is not appropriate for or does not agree to target a fasting glucose of 70-100 mg/dL \\[3.9 -5.6 mmol/L\\].\n* history of intolerance or hypersensitivity to Lantus™ or contraindication to Lantus™ or one of its excipients\n* used a formulation of insulin glargine other than Lantus™\n* has received injectable incretin-based therapy within the past 8 weeks\n* on a weight loss program and not in the maintenance phase, or has started a weight loss medication within the past 8 weeks\n* has undergone bariatric surgery within the past 12 months\n* is likely to require treatment for 2 or more consecutive weeks or repeated courses of corticosteroids (note: inhaled, nasal, and topical corticosteroids are permitted)\n* has undergone a surgical procedure within the past 4 weeks or has planned major surgery during the study\n* has new or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months, or has any following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder\n* has severe peripheral vascular disease\n* has high blood pressure\n* has chronic myopathy, or a progressive neurological or neuromuscular disorder\n* has active nephropathy\n* history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease\n* has human immunodeficiency virus (HIV)\n* has a hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n* history of malignancy in the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* history of melanoma, leukemia, lymphoma, or renal cell carcinoma\n* is currently being treated for hyperthyroidism or has been on a stable dose of thyroid hormone replacement therapy for \\<6 weeks\n* is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence\n* is pregnant or breast-feeding, or is expecting to conceive or donate eggs\n* has donated blood products or has had phlebotomy of \\>300 mL within the past 8 weeks or intends to donate blood products during the study\n* has poor mental function or works the night shift'}, 'identificationModule': {'nctId': 'NCT02059161', 'briefTitle': 'A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merck Sharp & Dohme LLC'}, 'officialTitle': 'A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 1 Diabetes Mellitus', 'orgStudyIdInfo': {'id': '1293-003'}, 'secondaryIdInfos': [{'id': '2011-003971-12', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MK-1293', 'description': 'MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).', 'interventionNames': ['Drug: MK-1293', 'Drug: Prandial Insulin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Lantus', 'description': 'Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \\>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).', 'interventionNames': ['Drug: Lantus™', 'Drug: Prandial Insulin']}], 'interventions': [{'name': 'MK-1293', 'type': 'DRUG', 'description': "MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.", 'armGroupLabels': ['MK-1293']}, {'name': 'Lantus™', 'type': 'DRUG', 'otherNames': ['Insulin glargine'], 'description': "Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.", 'armGroupLabels': ['Lantus']}, {'name': 'Prandial Insulin', 'type': 'DRUG', 'description': 'Participants will continue their prandial insulin during the study.', 'armGroupLabels': ['Lantus', 'MK-1293']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merck Sharp & Dohme LLC'}]}, 'ipdSharingStatementModule': {'url': 'http://engagezone.msd.com/ds_documentation.php', 'ipdSharing': 'YES', 'description': 'https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}